<DOC>
	<DOCNO>NCT02764047</DOCNO>
	<brief_summary>Evaluate effect supplementation probiotic liver change ( histological enzymatic ) , lipid profile gut microbiota patient nonalcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Probiotics Treatment NAFLD</brief_title>
	<detailed_description>Design The study single-center double blind , placebo control , parallel group study . Patients randomize receive either probiotic supplement ( 1.109 Lactobacillus acidophilus ATCC SD5221 1.109 Bifidobacterium lactis HN019 ) placebo 6 month . All participant receive individualize dietary couseling session nutritionist . Randomization Randomization perform use website www.randomization.com . The allocation sequence remain conceal throughout study . Researchers , outcome assessor patient blind treatment receive . The trial register www.clinicaltrials.gov . ( number NCT02764047 ) Intervention Patients receive probiotic placebo supplement identical medicine bottle maintain blinding . The instruction administration capsule take 1 capsule per day bedtime 1 cup water . Patients also advise keep medication use without change end study communicate investigator use antibiotic . Questionary - Profile risk factor fibrosis NASH The profile patient NASH analyze accord variable collect ( age , gender , smoking , diabetes , hypertension , high blood pressure , heart rate , weight , height , BMI , waist circumference , AST , ALT , total bilirubin , albumin , total cholesterol , HDL cholesterol , LDL cholesterol , triglyceride , glucose , insulin , C-reactive protein , platelet ) , well possible risk factor development disease . It believe interaction diet , intestinal microbiota genetic background important development progression NAFLD . Participants request bring medication use list pharmacist research center . During medication interview generic name , dose frequency register trained staff . Nutritional Physical assessment Height measure baseline confirm BMI . At 0 ( baseline ) , 3 6 month body weight measure use calibrated balance , waist circumference , systolic blood pressure , diastolic blood pressure , heart rate . Body composition assess baseline 6 month phase angle bioelectrical impedance analysis ( BIA ) method , hand grip strength . Biopsy , Fibromax NAFLD score Improvement liver injury define reduction fibrosis , steatosis inflammation liver biopsy noninvasive test Fibromax test NAFLD score vary degree . NAFLD score FibroMax ™ test ( Biopredictive , Paris , France ) , evaluate fibrosis , inflammation hepatic steatosis . Sensitivity , specificity , positive negative predictive value assess comparison non-invasive fibrosis assessment method liver biopsy . Hepatic transaminase ( AST , ALT ) assess well . Biochemical marker - General lab Cytokines sample At baseline , 3 6 month , fast blood sample take measurement plasma laboratory test ( AST , ALT , total bilirubin , albumin , total cholesterol , HDL cholesterol , LDL cholesterol , triglyceride , glucose , insulin , C-reactive protein , platelet ) , serum -1 leptin MCP quantify . To determine level serum leptin MCP-1 , 15 mL venous blood sample take antecubital vein , transfer tube without anticoagulant ( 4 mL ) . Blood sample collect 9:00 a.m. 11:00 a.m. , baseline ( PRE ) , 3 month 6 month . Tubes without anticoagulant centrifuge 1048g 10 min . Serum sample divide several aliquot store -20 °C analysis . Serum leptin MCP-1 level determine use enzyme-linked immunosorbent assay ( ELISA ) method , use specific kit ( Peprotech , EUA ) follow manufacturer 's instruction . All sample measure duplicate microplate reader SpectraMax M2e ( Molecular Devices , EUA ) . Intra-assay coefficient variation always &lt; 5.0 % , 3.8 % BDNF cortisol , respectively . Gut microbiota - Stool sample Fecal sample collect patient bottle deliver Nutrition Clinic Hepatology Hospital Santa Clara Santa Casa Hospital Complex . The sample transport Immunology Laboratory . Samples aliquoted 4 sample , frozen , store -20 -80 degrees freezer . At end collection , DNA extract ( MoBio PowerFecal® DNA Isolation Kit ) . DNA sample send University Institute Research Center Cardiology Pneumology University Quebec Laval . Genetic sequence microflora sample perform . Results analyze correlated clinical outcome . Food record Eligible patient submit food assessment use food frequency questionnaire validate liver disease , 24-hour recall survey use possible comparison food frequency questionnaire . The multiple-step method perform apply patient interview , aim improve collection accuracy reduce memory bias .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>18 year , patient NASH confirm biopsy within 6 month inclusion . Patients hepatitis B virus , hepatitis C virus , alcohol consumption significantly ( &gt; 14 drink per week woman &gt; 21 drink per week men ) ( Chalasani , 2012 ) , history decompensated liver disease ( ascites , esophageal varix , encephalopathy ) , hepatocellular carcinoma , steroid , methotrexate , amiodarone , tamoxifen , valproate , vitamin E past 6 month , previous surgery ( bariatric , gastric , intestinal resection ) , parenteral nutrition ( TPN ) last 6 month , pregnancy breastfeeding , history hypothyroidism , Cushing 's syndrome , diabetes type 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-alcoholic Fatty Liver Disease</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>NAFLD</keyword>
	<keyword>NASH</keyword>
</DOC>